CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
2.380
+0.020 (0.85%)
Jun 6, 2025, 4:00 PM - Market closed
CEL-SCI Market Cap
CEL-SCI has a market cap or net worth of $12.22 million as of June 6, 2025. Its market cap has decreased by -82.76% in one year.
Market Cap
12.22M
Enterprise Value
20.82M
1-Year Change
-82.76%
Ranking
Category
Stock Price
$2.38
Market Cap Chart
Since December 1, 1998, CEL-SCI's market cap has decreased from $1.63T to $12.22M, a decrease of -100.00%. That is a compound annual growth rate of -35.90%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Jun 6, 2025 | 7.20M | -70.73% |
Dec 31, 2024 | 24.60M | -81.90% |
Dec 29, 2023 | 135.90M | 32.46% |
Dec 30, 2022 | 102.60M | -66.58% |
Dec 31, 2021 | 307.00M | -33.78% |
Dec 31, 2020 | 463.60M | 43.22% |
Dec 31, 2019 | 323.70M | 297.18% |
Dec 31, 2018 | 81.50M | 226.00% |
Dec 29, 2017 | 25.00M | 96.85% |
Dec 30, 2016 | 12.70M | -73.60% |
Dec 31, 2015 | 48.10M | -9.42% |
Dec 31, 2014 | 53.10M | 80.61% |
Dec 31, 2013 | 29.40M | -60.16% |
Dec 31, 2012 | 73.80M | 10.81% |
Dec 30, 2011 | 66.60M | -60.45% |
Dec 31, 2010 | 168.40M | 25.11% |
Dec 31, 2009 | 134.60M | 300.60% |
Dec 31, 2008 | 33.60M | -42.37% |
Dec 31, 2007 | 58.30M | 27.85% |
Dec 29, 2006 | 45.60M | 25.27% |
Dec 30, 2005 | 36.40M | -16.13% |
Dec 31, 2004 | 43.40M | -99.97% |
Dec 31, 2002 | 143.38B | -77.89% |
Dec 31, 2001 | 648.64B | -36.67% |
Dec 29, 2000 | 1,024.17B | -35.06% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 691.15B |
Johnson & Johnson | 373.01B |
AbbVie | 335.32B |
Novo Nordisk | 332.47B |
UnitedHealth Group | 275.06B |
Abbott Laboratories | 232.41B |
Novartis AG | 231.17B |
AstraZeneca | 226.14B |